Commercial Alamar, Hemab, Kailera, and Seaport advance IPOs PharmaphorumThe last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.CommercialRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings. CommercialRead full story Post navigation Previous: Spyre drug for inflammatory bowel disease shows promise in early studyNext: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
